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Abstract 
Autoimmune hepatitis (AIH) is a form of chronic hepatitis of unknown etiology. It was 
first described in the 1950s as a form of chronic hepatitis noted in younger women. It 
was later termed lupoid hepatitis due to its association with autoantibodies before being 
named AIH in 1965. Corticosteroids and azathioprine have been the standard therapy for 
AIH, but due to treatment failures and toxicities from these medications, new 
medications are being investigated as possible treatment options. Rituximab has been 
used in various autoimmune disorders with good success. We report the case of a 
34-year-old Caucasian woman with a history of B cell lymphoma and concurrent AIH 
treated with rituximab. The diagnosis of AIH was made by classic serological and 
histological features. The patient was initially treated with steroids but had a progression 
of her disease as well as suffering toxicities from the steroids. She was then given eight 
weeks of rituximab with good improvement in both laboratory and histological findings. 
Introduction 
Autoimmune hepatitis (AIH) is a form of chronic hepatitis that can lead to end-stage 
liver disease and cirrhosis if left untreated. AIH was first described in the 1950s by 
Waldenstrom [1] and since that time much research has been done to better understand 
the pathogenesis of the disease [2]. The presence of autoantibodies and elevated levels of 
immunoglobulins found in AIH point toward an autoimmune etiology, as does its 
response to immunosuppresants [3]. The mainstay of treatment has been with 
corticosteroids and azathioprine [4]. Treatment failures with standard regimens have 
been quoted to occur in at least 9% of treated patients [5]. Treatment failures are usually 
treated by the administration of high-dose steroids with or without azathioprine with the 
risk of increased toxicities [5]. Several other medications have been tried with varying 
degrees of success, including myophenil and tacrolimus [5]. Rituximab is a potential  
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treatment option in those who have failed conventional treatment or who cannot tolerate 
current treatment strategies. Rituximab functions as a chimeric monoclonal antibody 
against the CD20 protein which is found primarily on the surface of B lymphocytes. 
Rituximab induces B cell depletion and thus suppresses the production of pathogenic 
antibodies. Rituximab has a relatively favorable side effect profile and may become a new 
treatment option in AIH. 
Case Report 
A 27-year-old female was in her usual state of health when she presented to her primary care 
physician with complaints of left postauricular pain for about one month duration. Review of symptoms 
was positive for fevers, chills, fatigue, night sweats and abdominal pain. Her past medical history 
included primary biliary cirrhosis, migraine headaches, gastric esophageal reflux disease and 
endometriosis. Social history did not reveal any alcohol use. Her medications included ursodiol 300 mg 
three times a day, atarax 25 mg three times a day, and nexium 40 mg every day. Her family history was 
significant for a sister with systemic lupus erythematosus and an aunt with systemic lupus 
erythematosus and scleroderma. Physical exam revealed normal vital signs, with a 0.5 × 0.5 cm 
nontender immobile lymph node in the right posterior auricular area and a 2 × 2 cm nontender 
immobile lymph node in the left posterior auricular area. Abdominal examination revealed 
hepatomegaly and right upper quadrant tenderness. No other lymphadenopathy was appreciated. 
Laboratory data revealed alanine aminotransferase (ALT) 92 IU/l, aspartate aminotransferase (AST) 
81 IU/l, alkaline phosphatase 387 IU/l and total bilirubin 0.3 mg/dl. Her previous aminotransferases had 
been normal. The left lymph node was biopsied and the pathology report revealed a marginal B cell 
lymphoma with the majority of lymphocytes immunoreactive to CD20. Further staging was done, 
including contrast-enhanced computed tomography scans of the abdomen/pelvis and chest, positron 
emission tomography and a bone marrow biopsy and no other sites of disease were found. The patient 
was given a diagnosis of stage 2b marginal zone B cell lymphoma. At that time, the tumor board met to 
discuss the patient’s plan of care. There was some concern about initiating chemotherapy given her 
young age and fear of toxicities and it was decided to first evaluate her liver disease before 
recommending any further therapy. 
She was then seen by a hepatologist for her elevated aminotransferases as well as for her continued 
abdominal pain. It was decided to proceed with a liver biopsy. Biopsy revealed interface and lobular 
hepatitis with an abundance of plasma cells and stage 2 fibrosis as well as a large granuloma centered on 
a bile duct. In addition, her antinuclear antibody (ANA) titer was noted to be positive at 1:640. Anti 
smooth muscle antibodies (ASMA) and anti liver-kidney microsomal antibodies (ALK) were checked 
and were negative. Her immunoglobulin G (IgG) level was noted to be 2,320 mg/dl. Laboratory tests for 
hepatitis B virus antigen and anti hepatitis C virus antibody were negative. Abdominal ultrasonography 
revealed a liver of normal size and echogenicity. She was given the diagnosis of AIH with overlap 
primary biliary cirrhosis and was started on prednisone 30 mg a day with a planned taper. Her 
symptoms and aminotransferases improved slightly but several months later she had an increase in 
abdominal pain and fatigue and it was noted on laboratory examination that her aminotransferases had 
again increased. She had also gained 21 pounds since being started on prednisone. She then had a repeat 
liver biopsy which showed worsening of her hepatic fibrosis. At this time, there was concern that the 
patient was not tolerating steroids well and was having progression of her liver disease. Her physicians 
were concerned about attempting treatment with immunosuppressants such as azathioprine given her 
history of B cell lymphoma. It was then decided to start her on weekly therapy of rituximab to address 
both her B cell lymphoma and her AIH. She was given eight weekly infusions of rituximab 375 mg/m
2. 
During the course of this treatment, her physicians were able to taper down her steroids to 7 mg a day. 
After this treatment course, her abdominal pain and fatigue resolved and her laboratory exams revealed 
AST 31 IU/l, ALT 55 IU/l, alkaline phosphatase 186 IU/l, and total bilirubin 0.5 mg/dl. Her 
lymphadenopathy completely resolved.  
The patient did well until several months later when she began to again have right upper quadrant 
abdominal pain as well as an increase in her aminotransferases: AST 49 IU/l, ALT 82 IU/l. At that time 
quantitative immunoglobulin level was checked and revealed an IgG level of 1,562 mg/dl. It was decided 
to treat her with another four weeks of rituximab therapy. After this, her aminotransferases normalized, 
her IgG level decreased and her symptoms resolved and she was able to be weaned off her steroids  
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completely. Repeat liver biopsy revealed mild chronic inflammation with no significant number of 
plasma cells and no interface hepatitis. There was only mild portal fibrosis present. 
At follow-up six years later, the patient remained stable with normal aminotransferase levels, and a 
repeat liver biopsy revealed quiescent disease with minimal chronic inflammation and no interface 
hepatitis. Her B cell lymphoma remains in remission since her first rituximab treatment.  
Discussion 
AIH is a form of chronic hepatitis of unknown cause that can lead to end-stage liver 
disease and cirrhosis if left untreated. Its association with circulating antibodies and 
elevated immunoglobulins supports an autoimmune etiology.
 It was first described in the 
1950s and since that time much research has been done to better understand the etiology 
and natural history of the disease. An accepted hypothesis of the pathogenesis of AIH is 
that there exists a genetic predisposition and that this combined with an unknown 
environmental trigger leads to a cell-mediated attack on certain liver antigens [6]. There 
appears to be an abnormal expression of class II human leukocyte antigens on the 
antigen-presenting cells presented to helper T cells [6]. It is believed this aberrant human 
leukocyte antigens display is a result of an infection or of an exposure to an unknown 
environmental trigger. There is a paucity of epidemiologic data available on AIH but one 
recent study from New Zealand revealed age-standardized incidence and prevalence to be 
1.7 and 18.9 per 100,000, respectively. The authors also noted a higher prevalence in 
Caucasians and the majority of cases presented after 40 years of age [7], although AIH 
does occur in children and young adults. As with most autoimmune diseases, there is a 
higher female predominance [7]. To help diagnose AIH, a diagnostic scoring system was 
composed by an international panel initially in 1993 and revised in 1999 (table 1) [8], 
which includes histological and serological findings, the presence of autoantibodies and 
exclusion of other causes of hepatitis [8]. 
Patients typically present with nonspecific symptoms that may include abdominal 
pain, nausea, jaundice and fatigue. There is much variability in disease presentation, and 
patients may be asymptomatic or present with fulminant hepatic failure [9]. The disease 
has characteristic histological findings of a chronic mononuclear infiltrate typically 
involving the limiting plate (interface hepatitis) usually with a rich plasma cell infiltrate, 
and AIH is also associated with lobular hepatitis (fig. 1, fig. 2) [10]. Lab work tends to 
reveal elevations in aminotransferases more so than abnormalities in bilirubin and 
alkaline phosphotase [3]. AIH is also associated with elevated levels of serum globulins, 
particularly IgG, which are generally 1.2 to 3 times the normal level [3]. In addition, AIH 
is associated with the presence of autoantibodies, including ANA, ASMA, ALK, 
perinuclear anti-neutrophil cytoplasmic antibodies, and anti liver cytosol type 1 
antibodies (anti-LC1) [8, 11]. 
Two types of AIH have been identified and classified as type 1 and 2. Type 1 accounts 
for roughly 80% of cases and tends to have positive serology for ANA, ASMA or both 
[12]. Type 2 is less common and characterized by ALK or anti-LC1 antibodies. In 
addition to the differences in serological findings, type 2 AIH also seems to affect younger 
adults and children and to have more treatment failures [13]. 
Two well-established treatment regimens are effective in AIH [14] which include either 
prednisone alone or prednisone in combination with azathioprine. Ongoing research is  
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being conducted to try and identify patient features that may lead to treatment failure, 
which occurs at least 9% of the time [5]. Other medications have been investigated for 
treatment failures, including tacrolimus, cyclophosphamide, ursodeoxycholic acid and 
mycophenolate mofetil [15], with varying degrees of success. 
Rituximab is an interesting therapeutic option for AIH as it works primarily on the 
humoral immune response by inducing B lymphocyte depletion and decreased 
production of autoantibodies. AIH is known to involve more of a cell-mediated immune 
process, but rituximab has been used successfully in other diseases which are believed to 
involve a primarily cell-mediated process, including multiple sclerosis [16]. It is believed 
that rituximab works in these situations by indirectly altering cell-mediated responses. 
Mouse models have shown that B lymphocyte depletion impairs CD4+ T cell activation in 
response to pathogen challenges, which may in part explain how rituximab is effective in 
primarily cell-mediated disease processes, including AIH [16]. 
Rituximab has a relatively favorable side effect profile and thus may be a good option 
for treatment failures and perhaps even initial management of AIH in individual cases 
where patients are poor candidates for steroids and azathioprine. More studies are needed 
to investigate this further. 
Conclusion 
Our patient presented with concurrent diagnoses of B cell lymphoma and AIH. She 
was initially treated with steroids for her AIH but was intolerant to the side effects and 
also showed progression of her liver disease. Due to her history of B cell lymphoma, it was 
then decided to pursue treatment with rituximab. After receiving treatment with 
rituximab the patient achieved both clinical and histological remission. Further studies 
need to be performed to further elicit the role of rituximab in AIH. 
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Table 1. Scoring system for the diagnosis of AIH [8] 
Category  <Factor  <Score 
Gender  <female  0+2 
Alk phos: AST (or ALT) ratio  >3  0−2 
 <1.5  0+2 
>2.0  0+3 
<1.5–2.0  0+2 
<1.0–1.5  0+1 
γ-Globulin or IgG (times above upper  
limit of normal) 
<1.0  0<0 
ANA, SMA, or anti-LKM1 titers  >1:80  0+3 
  <1:80  0+2 
  <1:40  0+1 
 <1:40 0<0 
AMA  <positive  0−4 
Viral markers of active infection  <positive  0−3 
  <negative  0+3 
Hepatotoxic drugs  <yes  0−4 
  <no  0+1 
Alcohol <25  g/d  0+2 
 >60  g/d  0−2 
Concurrent immune disease  <any nonhepatic disease of an immune nature  0+2 
Other autoantibodies
a  <anti-SLA/LP, actin, LC1, pANCA  0+2 
Histologic features  <interface hepatitis  0+3 
  <plasma cells  0+1 
  <rosettes  0+1 
  <none of above  0−5 
  <biliary changes
b  0−3 
  <atypical features
c  0−3 
HLA  <DR3 or DR4  0+1 
Treatment response  <remission alone  0+2 
  <remission with relapse  0+3 
Pretreatment score     
Definite diagnosis    >15 
Probable diagnosis    <10–15 
Posttreatment score     
Definite diagnosis    >17 
Probable diagnosis    <12–17 
Alk phos = serum alkaline phosphatase level; ALT = serum alanine aminotransferase level; AMA = 
antimitochondrial antibodies; ANA = antinuclear antibodies; AST = serum aspartate aminotransferase 
level; HLA = human leukocyte antigen; IgG = serum immunoglobulin G level; anti-LKM1 = antibodies to 
liver/kidney microsome type 1; SMA = smooth muscle antibodies; HLA-DR3, DR4 = human leukocyte 
antigen-D.  
aUnconventional or generally unavailable antibodies associated with liver disease include perinuclear 
antineutrophil cytoplasmic antibodies (pANCA) and antibodies to actin, soluble liver antigen/liver 
pancreas (anti-SLA/LP), asialoglycoprotein receptor, and liver cytosol type 1 (LC1).  
bIncludes destructive cholangitis, nondestructive cholangitis, or ductopenia.  
cIncludes steatosis, iron overload consistent with genetic hemochromatosis, alcoholic hepatitis, viral 
features (ground-glass hepatocytes), or inclusions (cytomegalovirus, herpes simplex).  
Data from [17]. 
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Fig. 1. Arrow: interface hepatitis. Note the lymphocytic infiltrate that extends from the portal tract into 
the liver lobule. 
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Fig. 2. Arrow: expanded portal inflammation with lymphocytic aggregate. 
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